JP2017503481A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503481A5 JP2017503481A5 JP2016536527A JP2016536527A JP2017503481A5 JP 2017503481 A5 JP2017503481 A5 JP 2017503481A5 JP 2016536527 A JP2016536527 A JP 2016536527A JP 2016536527 A JP2016536527 A JP 2016536527A JP 2017503481 A5 JP2017503481 A5 JP 2017503481A5
- Authority
- JP
- Japan
- Prior art keywords
- dlbcl
- lenalidomide
- patient
- pharmaceutically acceptable
- isomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913046P | 2013-12-06 | 2013-12-06 | |
| US61/913,046 | 2013-12-06 | ||
| PCT/US2014/068767 WO2015085160A2 (en) | 2013-12-06 | 2014-12-05 | Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017503481A JP2017503481A (ja) | 2017-02-02 |
| JP2017503481A5 true JP2017503481A5 (2) | 2018-01-18 |
Family
ID=53274284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536527A Pending JP2017503481A (ja) | 2013-12-06 | 2014-12-05 | 血液癌を治療する方法及び免疫調節療法に対する臨床的感受性の予測因子としてのバイオマーカーの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160312292A1 (2) |
| EP (1) | EP3077547A4 (2) |
| JP (1) | JP2017503481A (2) |
| KR (1) | KR20160090390A (2) |
| AU (1) | AU2014360316A1 (2) |
| BR (1) | BR112016012792A2 (2) |
| CA (1) | CA2932266A1 (2) |
| EA (1) | EA201691143A1 (2) |
| IL (1) | IL245936A0 (2) |
| MX (1) | MX2016007179A (2) |
| PH (1) | PH12016501023A1 (2) |
| WO (1) | WO2015085160A2 (2) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160282354A1 (en) | 2013-11-08 | 2016-09-29 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| EP3996039A1 (en) * | 2014-10-17 | 2022-05-11 | Stichting Maastricht Radiation Oncology "Maastro-Clinic" | Image analysis method supporting illness development prediction for a neoplasm in a human or animal body |
| WO2016196580A1 (en) | 2015-06-02 | 2016-12-08 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| WO2017044793A1 (en) | 2015-09-11 | 2017-03-16 | The Brigham And Women's Hospital, Inc. | Methods of characterizing resistance to modulators of cereblon |
| WO2017053555A1 (en) * | 2015-09-25 | 2017-03-30 | Celgene Corporation | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| KR20180095094A (ko) | 2016-01-08 | 2018-08-24 | 셀진 코포레이션 | 암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도 |
| EP3674416A4 (en) * | 2017-09-29 | 2021-05-26 | Kyushu University, National University Corporation | METHOD AND KIT FOR PREDICTING THE THERAPEUTIC EFFECTIVENESS OF CHEMOTHERAPY FOR PATIENTS WITH DIFFUSED LARGE B-CELL LYMPHOMA |
| IL292305A (en) * | 2019-10-21 | 2022-06-01 | Celgene Corp | Methods for the treatment of hematological cancer and the use of associated biomarkers for 2-(2,6-deoxypyridin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isodonyl 1,3-discussion |
| WO2024258819A1 (en) * | 2023-06-15 | 2024-12-19 | The Broad Institute, Inc. | Neoplastic cytotoxicity induced by glycosylation |
| FR3158743A1 (fr) * | 2024-01-30 | 2025-08-01 | Universite Grenoble Alpes | Biomarqueurs et outil pronostique pour les patients atteint de lymphomes b diffus a grandes cellules |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009085234A2 (en) * | 2007-12-20 | 2009-07-09 | Signal Pharmaceuticals, Inc. | Use of micro-rna as a biomarker of immunomodulatory drug activity |
| KR20130038838A (ko) * | 2010-03-12 | 2013-04-18 | 셀진 코포레이션 | 레날리도미드, 및 예측 인자로서 유전자 및 단백질 바이오마커를 사용한 비호지킨 림프종의 치료 방법 |
| AU2012249491B2 (en) * | 2011-04-29 | 2016-12-15 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
-
2014
- 2014-12-05 EP EP14867978.0A patent/EP3077547A4/en not_active Withdrawn
- 2014-12-05 WO PCT/US2014/068767 patent/WO2015085160A2/en not_active Ceased
- 2014-12-05 MX MX2016007179A patent/MX2016007179A/es unknown
- 2014-12-05 AU AU2014360316A patent/AU2014360316A1/en not_active Abandoned
- 2014-12-05 JP JP2016536527A patent/JP2017503481A/ja active Pending
- 2014-12-05 CA CA2932266A patent/CA2932266A1/en not_active Abandoned
- 2014-12-05 BR BR112016012792A patent/BR112016012792A2/pt not_active Application Discontinuation
- 2014-12-05 KR KR1020167017539A patent/KR20160090390A/ko not_active Withdrawn
- 2014-12-05 EA EA201691143A patent/EA201691143A1/ru unknown
- 2014-12-05 US US15/101,866 patent/US20160312292A1/en not_active Abandoned
-
2016
- 2016-05-31 PH PH12016501023A patent/PH12016501023A1/en unknown
- 2016-05-31 IL IL245936A patent/IL245936A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503481A5 (2) | ||
| JP2016500110A5 (2) | ||
| RU2015125575A (ru) | Композиции и способы для лечения злокачественной опухоли | |
| Tan et al. | Identification of circulating long non-coding RNA GAS5 as a potential biomarker for non-small cell lung cancer diagnosisnon-small cell lung cancer, long non-coding RNA, plasma, GAS5, biomarker | |
| Wu et al. | Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone | |
| Chan et al. | Personalized therapy for hepatocellular carcinoma: Where are we now? | |
| JP2014144959A5 (2) | ||
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| JO3681B1 (ar) | استخدام مجموعات الجين الطافر fgfr في الكشف عن مرضى السرطان الذين سوف يستجيبون للعلاج بمثبط fgfr | |
| BR112017025254A2 (pt) | ?métodos para detecção de pelo menos uma mutação em uma pluralidade de genes relacionados ao câncer, selecionar um indivíduo para tratamento e prever a probabilidade de capacidade de resposta ao tratamento? | |
| JP2016537010A5 (2) | ||
| Jang et al. | A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma | |
| JP2016536303A5 (2) | ||
| WO2018007872A9 (en) | Biomarkers for inflammatory bowel disease | |
| JP2016501013A5 (2) | ||
| JP2015530877A5 (2) | ||
| Chen et al. | CCL22 and IL-37 inhibit the proliferation and epithelial-mesenchymal transition process of NSCLC A549 cells | |
| Zhang et al. | Prognostic significance of combining VEGFA, FLT1 and KDR mRNA expression in lung cancer | |
| Chen et al. | Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel | |
| Yu et al. | A meta‐analysis: micro RNA s’ prognostic function in patients with nonsmall cell lung cancer | |
| JP2016510591A5 (2) | ||
| Wang et al. | Effects of miR-455 on PIK3R1 gene expression regulation and kidney cancer cell functions. | |
| MX2016012718A (es) | Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina. | |
| WO2023023592A1 (en) | Repurposing drugs for non-small cell lung cancer | |
| Bialopiotrowicz et al. | Microenvironment-induced expression of PIM kinases supports chronic lymphocytic leukemia cells survival and promotes CXCR4-mTOR pathway dependent migration |